Theriva Biologics Files 8-K with Financials and Exhibits
Ticker: TOVX · Form: 8-K · Filed: Oct 24, 2025 · CIK: 894158
| Field | Detail |
|---|---|
| Company | Theriva Biologics, Inc. (TOVX) |
| Form Type | 8-K |
| Filed Date | Oct 24, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $4,019,597 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-statements, company-name-change
TL;DR
Theriva Biologics (formerly Synthetic Biologics) filed an 8-K with financials on 10/24/25.
AI Summary
On October 24, 2025, Theriva Biologics, Inc. filed an 8-K report. The filing indicates a change in the company's reporting status and includes financial statements and exhibits. Theriva Biologics, Inc. was formerly known as Synthetic Biologics, Inc., Adeona Pharmaceuticals, Inc., and Pipex Pharmaceuticals, Inc., with name changes occurring on March 5, 2012, October 27, 2008, and December 14, 2006, respectively.
Why It Matters
This 8-K filing provides updated information and financial statements for Theriva Biologics, Inc., which is crucial for investors to assess the company's current financial health and operational status.
Risk Assessment
Risk Level: low — This filing is a routine 8-K report containing financial statements and exhibits, not indicating any immediate adverse events.
Key Players & Entities
- Theriva Biologics, Inc. (company) — Registrant
- October 24, 2025 (date) — Date of earliest event reported
- Synthetic Biologics, Inc. (company) — Former company name
- Adeona Pharmaceuticals, Inc. (company) — Former company name
- Pipex Pharmaceuticals, Inc. (company) — Former company name
- March 5, 2012 (date) — Date of name change
- October 27, 2008 (date) — Date of name change
- December 14, 2006 (date) — Date of name change
FAQ
What is the primary purpose of this 8-K filing by Theriva Biologics, Inc.?
The primary purpose of this 8-K filing is to report other events and to provide financial statements and exhibits as of October 24, 2025.
What was Theriva Biologics, Inc. previously named?
Theriva Biologics, Inc. was previously named Synthetic Biologics, Inc., Adeona Pharmaceuticals, Inc., and Pipex Pharmaceuticals, Inc.
When did the company last change its name from Synthetic Biologics, Inc.?
The company changed its name from Synthetic Biologics, Inc. on March 5, 2012.
In which state is Theriva Biologics, Inc. incorporated?
Theriva Biologics, Inc. is incorporated in Nevada.
What is the business address of Theriva Biologics, Inc.?
The business address of Theriva Biologics, Inc. is 9605 Medical Center Drive, Suite 270, Rockville, MD 20850.
Filing Stats: 853 words · 3 min read · ~3 pages · Grade level 11.2 · Accepted 2025-10-24 15:26:23
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share TOVX NYSE American Indica
- $4,019,597 — relating to the offer and sale of up to $4,019,597 of shares of the Company's common stock
Filing Documents
- tm2529425d2_8k.htm (8-K) — 29KB
- tm2529425d2_ex5-1.htm (EX-5.1) — 10KB
- tm2529425d2_ex5-1img001.jpg (GRAPHIC) — 3KB
- 0001104659-25-102104.txt ( ) — 211KB
- syn-20251024.xsd (EX-101.SCH) — 3KB
- syn-20251024_lab.xml (EX-101.LAB) — 33KB
- syn-20251024_pre.xml (EX-101.PRE) — 22KB
- tm2529425d2_8k_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On October 24, 2025, Theriva Biologics, Inc. (the "Company") filed a prospectus supplement and the accompanying base prospectus (the "Prospectus Supplement") to its Registration Statement on Form S-3, as amended (File No. 333-279077), which Form S-3 was declared effective by the Securities and Exchange Commission (the "Commission") on September 25, 2024 (the "Registration Statement"), relating to the offer and sale of up to $4,019,597 of shares of the Company's common stock, par value $0.001 per share (the "common stock"), from time to time through or directly to A.G.P./Alliance Global Partners (the "Sales Agent") pursuant to the terms of that certain Amended and Restated At Market Issuance Sales Agreement, dated February 9, 2021, as amended by Amendment No. 1 thereto, dated May 3, 2021, as further amended by Amendment No. 2 thereto, dated May 2, 2024 (the "Sales Agreement"). Sales of the common stock, if any, under the Prospectus Supplement will be made by any method permitted that is deemed an "at the market offering" as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the "Securities Act"). The Sales Agent is not required to sell any specific amount, but will act as our Sales Agent using commercially reasonable efforts consistent with its normal trading and sales practices. There is no arrangement for funds to be received in any escrow, trust or similar arrangement. The Sales Agent will be entitled to compensation at a commission rate equal to up to 3.0% of the gross sales price per share sold. In connection with the sale of the common stock on our behalf, the Sales Agent will be deemed to be an "underwriter" within the meaning of the Securities Act and the compensation of the Sales Agent will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to the Sales Agent with respect to certain liabilities, including liabilities under the Sec
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. The following exhibits are filed with this Current Report on Form 8-K: Exhibit Number Description 5.1 Opinion of Parsons Behle & Latimer 23.1 Consent of Parsons Behle & Latimer (included in Exhibit 5.1 hereof) 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within in the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 24, 2025 THERIVA BIOLOGICS, INC. By: /s/ Steven A. Shallcross Name: Steven A. Shallcross Title: Chief Executive Officer and Chief Financial Officer